These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 28962071)

  • 1. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
    Desborough M; Hadjinicolaou AV; Chaimani A; Trivella M; Vyas P; Doree C; Hopewell S; Stanworth SJ; Estcourt LJ
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012055. PubMed ID: 27797129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
    Zhang X; Chuai Y; Nie W; Wang A; Dai G
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic platelet transfusions prior to surgery for people with a low platelet count.
    Estcourt LJ; Malouf R; Doree C; Trivella M; Hopewell S; Birchall J
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012779. PubMed ID: 30221749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.
    Desborough M; Estcourt LJ; Doree C; Trivella M; Hopewell S; Stanworth SJ; Murphy MF
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010982. PubMed ID: 27548292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
    Zeng Y; Duan X; Xu J; Ni X
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD008235. PubMed ID: 21735426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
    Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
    Sci Rep; 2018 Jan; 8(1):576. PubMed ID: 29330464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
    Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
    PLoS One; 2018; 13(6):e0198504. PubMed ID: 29856837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerobic physical exercise for adult patients with haematological malignancies.
    Knips L; Bergenthal N; Streckmann F; Monsef I; Elter T; Skoetz N
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009075. PubMed ID: 30702150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.
    Prica A; Sholzberg M; Buckstein R
    Br J Haematol; 2014 Dec; 167(5):626-38. PubMed ID: 25155450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
    Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
    Giagounidis A; Mufti GJ; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Hu K; Woodard P; Yang AS; Kantarjian HM
    Cancer; 2014 Jun; 120(12):1838-46. PubMed ID: 24706489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
    Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)).
    Küley-Bagheri Y; Kreuzer KA; Monsef I; Lübbert M; Skoetz N
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD011960. PubMed ID: 30080246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes.
    Hutzschenreuter F; Monsef I; Kreuzer KA; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009310. PubMed ID: 26880256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.